QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
🔍 How will access to new orphan drugs look like in the future?
Quantify Research‘s own Konstantin Macheridis shares insights in a newly published article on access to treatments for rare diseases. The Swedish HTA-agency Tandvårds- och läkemedelsförmånsverket, TLV has undertaken development work to increase access to orphan drugs through the national reimbursement system. The hope is that it will lead to improved access to orphan drugs – […]
Quantify Finland at the HTA Medications 2025 Event
This week, experts from the Quantify Research Finland group took part in HTA of Medications 2025, hosted by Pharmaca.
It was a day full of rich discussions and valuable insights with top HTA professionals from government and industry.
The perspectives we gained are already feeding into our Market Access & Strategy work, helping us better support our clients navigating the evolving HTA landscape in Finland.
Here […]
Quantify warmly welcomes Laura to the team!
We are excited to welcome Laura Tølløse to the Quantify Research team, expanding our capabilities in Denmark!
🧠 Laura has a Master of Science in Public Health from the University of Copenhagen (Københavns Universitet), where she utilised Danish registry data to investigate the impact of an educational interventions among preventive home visitors on several health outcomes among elderly receiving the home visits.
👩💻 In […]
How do we assess the value of medicines – and what´s next for HTA in Finland?
Quantify Research‘s Finnish team is excited to take part in Pharma Academy’s event on Health Technology Assessment (HTA) on May 21st, 2025!
This event will explore how we assess the therapeutic and economic value of treatments, how real-world data supports decision-making, and how HTA is evolving in both national and international contexts.
🔍 Key discussions points:
🟢 HTA’s role in access and reimbursement decisions
🟢 Using real-world […]